Charles J. Ryan MD
Genitourinary Oncology
Member and Attending Genitourinary Oncology Service Memorial Sloan Kettering Cancer Center
480 Red Hill RoadMiddletown, NJ 07748
Overview of Dr. Ryan
Dr. Charles Ryan is an oncologist in Middletown, NJ and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center, UCSF Medical Center, Zuckerberg San Francisco General Hospital and Trauma Center, and M Health Fairview University of Minnesota Medical Center. He received his medical degree from University of Wisconsin School of Medicine & Public Health and has been in practice 30 years. He is one of 160 doctors at UCSF Medical Center and one of 48 doctors at Zuckerberg San Francisco General Hospital and Trauma Center who specialize in Oncology. He also speaks multiple languages, including Spanish. He has more than 100 publications and over 500 citings.
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2000 - 2003
University of Wisconsin Hospitals and ClinicsResidency, Internal Medicine, 1996 - 2000
University of Wisconsin School of Medicine & Public HealthClass of 1996
Certifications & Licensure
NJ State Medical License 2024 - 2027
CA State Medical License 2003 - 2026
NY State Medical License 2000 - 2026
MN State Medical License 2018 - 2023
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory EHR Suite, Epic Systems Corporation, 2013-2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2013-2014, 2016-2017
Clinical Trials
- Ketoconazole, Hydrocortisone, and GM-CSF in Treating Patients With Progressive Prostate Cancer After Hormone Therapy Start of enrollment: 2004 Apr 01
- Nordihydroguaiaretic Acid in Treating Patients With Nonmetastatic Relapsed Prostate Cancer Start of enrollment: 2005 Jun 01
- Sorafenib and RAD001 Renal Cell Carcinoma Start of enrollment: 2006 Oct 01
Publications & Presentations
PubMed
- 4 citationsPathogenic Genomic Alterations in Circulating Tumor DNA Predict Overall Survival in Men with Metastatic Castrate-resistant Prostate Cancer.Susan Halabi, Siyuan Guo, Bin Luo, Chenxi Yu, Todd P Knutson
European Urology. 2026-04-01 - Clinical Utility of Transcriptomic Signatures to Identify Androgen Receptor and Neuroendocrine Signaling in Prostate Cancer.Yu-Wei Chen, Joanne Xiu, Kelsey Anne Poorman, Charles J Ryan, Brady Gilg
JCO Precision Oncology. 2026-03-01 - Trial Design and Objectives for Patients With Prostate Cancer: Recommendations From the Prostate Cancer Working Group 4.Andrew J Armstrong, Michael J Morris, Wassim Abida, Rahul R Aggarwal, Emmanuel S Antonarakis
Journal of Clinical Oncology. 2026-02-26
Lectures
- Considerations for Systemic Therapy in Optimal Management of Oligometastatic DiseaseASCO Annual Meeting 2019 - Chicago, IL - 6/2/2019
Other
- Castrate resistant prostate cancer: Treatments targeting the androgen pathwayRyan CJ, Dawson NA
http://www.uptodate.com/contents/castrate-resistant-prostate-cancer-treatments-targeting-the-androge
UpToDate, Wolters Kluwer Health - 2013-02-21
Press Mentions
What to Know About Complementary Therapies for Prostate CancerDecember 13th, 2024- Successes and Setbacks in Prostate Cancer Care: Seeking the Right Treatment for the Right Patient at the Right TimeJuly 23rd, 2024
- The Prostate Cancer Foundation Launches ‘Black Men: Know Your Risk’ Campaign and Teams up with Atlanta Hawks for ‘Black History Month Assist Challenge’ to Raise Awareness and Funds for Prostate Cancer ResearchFebruary 1st, 2023
Other Languages
- Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
